Immunisations in solid-organ transplant recipients

Lancet

Volumn 359, Issue 9310, 2002, Pages 957-965

  Stark, Klaus ^a,b   Günther, Matthias ^a   Schönfeld, Christian ^a   Tullius, Stefan G ^a   Bienzle, Ulrich ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DIPHTHERIA TETANUS TOXOID; INACTIVATED VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MYCOPHENOLIC ACID; ORAL POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; RAPAMYCIN; RECOMBINANT VACCINE; TACROLIMUS; TRIPLE VACCINE;

B LYMPHOCYTE; DISEASE SEVERITY; GRAFT REJECTION; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RATE; INFLUENZA; KIDNEY TRANSPLANTATION; MEASLES; POLIOMYELITIS; PRIORITY JOURNAL; RECIPIENT; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SAFETY; SEROCONVERSION; SIGNAL TRANSDUCTION; STREPTOCOCCUS INFECTION; T LYMPHOCYTE; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

EID: 0037117149     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08028-5     Document Type: Review

References (94)

1. Improved graft survival after renal transplantation in the United States, 1988 to 1996
2. Infections in solid-organ transplant recipients
3. T-cell-dependent B cell activation
4. The development and repertoire of B-1 cells (CD-5 B-cells)
5. Pharmacology of immunosuppressive medications in renal transplantation
6. The pharmacology of azathioprine
7. The mechanism of action of cyclosporin A and FK506
8. Rapamycin in transplantation: A review of the evidence
9. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin
10. Preferential suppression of lymphocyte proliferation by myco-phenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation
11. Current situation and control strategies for resurgence of diphtheria in newly independent states of the former Soviet Union
12. Immunity to diphtheria and tetanus in a young population on a dialysis regimen or with a renal transplant
13. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients
14. Duration of immunity to diphtheria and tetanus in young kidney transplant patients
15. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure
16. Routine immunizations in adult renal transplant recipients
17. Immunity to poliomyelitis, diphtheria and tetanus in pediatric patients before and after renal or liver transplantation
18. Influenza infection in patients before and after liver transplantation
19. Prevention and treatment of influenza in immunocompromised patients
20. Influenza vaccination in liver transplant recipients
21. Influenza vaccination in renal transplant patients is safe and serologically effective
22. Effective immunization against influenza in pediatric renal transplant recipients
23. The immunogenicity of influenza virus vaccine in solid organ transplant recipients
24. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation
25. Efficacy of influenza vaccination in adult liver transplant recipients
26. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols
27. Influenza vaccination following liver transplantation in children
28. Antibody response to influenza immunisation in patients after heart transplantation
29. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporin, but not azathioprine
30. Suppression of the humoral response by mycophenolate mofetil
31. Safety of influenza vaccine in heart transplant recipients
32. Liver transplantation in European patients with the hepatitis B surface antigen
33. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation
34. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor
35. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen
36. Immunization of health-care workers: Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee
37. Are booster immunisations needed for lifelong hepatitis B immunity?
38. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence
39. Use of licensed vaccines for active immunization of the immunocompromised host
40. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients
41. Hepatitis B vaccine in hemodialysis patients with hepatitis C virus infection
42. Response to hepatitis B vaccination by liver transplant candidates
43. Hepatitis B vaccination results in 140 liver transplant recipients
44. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation
45. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation?
46. Failure of vaccination against hepatitis B with Gen H-B-Vax-D in immunosuppressed heart transplant recipients
47. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients
48. Hepatitis B vaccination of immunsuppressed heart transplant recipients with vaccine Hepa Gene 3 containing pre-S1, pre-S2 and S gene products
49. Response to an extra dose of hepatitis B vaccine and specific antibody persistence in non-responders to primary immunization
50. A hepatitis B vaccine formulated with a novel adjuvant system
51. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine
52. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination
53. Prevention of fungal and hepatitis virus infections in liver transplantation
54. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
55. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation
56. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up
57. Hepatitis B immunglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus reccurrence after liver transplantation
58. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
59. Hepatitis A vaccine
60. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients
61. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients
62. Rapid decline of antibodies after hepatitis A immunisation in liver and renal transplant recipients
63. Differences between cyclosporin A and tacrolimus in organ transplantation
64. Epidemiologic features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: Findings of a French survey
65. Increased risk of pneumococcal infections in cardiac transplant recipients
66. New 23-valent pneumococcal vaccine in relation to pneumococcal serotypes in systemic and non-systemic disease
67. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
68. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory
69. Efficacy of a pneumococcal conjugate vaccine against acute otitis media
70. Policy Statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis
71. Age-associated differences in immunglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination
72. Pneumococcal immunization after heart and liver transplantation: Immune responses in immunosuppressed patients and in healthy controls
73. T-cell-independent antigens type-2
74. Pneumococcal vaccine response in cirrhosis and liver transplantation
75. Immunization of renal transplant recipients with pneumococcal polysaccharide vaccine
76. Immunogenicity of pneumococcal vaccine in heart transplant recipients
77. Safety of revaccination with pneumococcal polysaccharide vaccine
78. Varicella in the first year after renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)
79. Lengthy tale of varicella vaccine development finally nears a clinically useful conclusion
80. Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
81. Varicella and zoster after kidney transplantation: Long-term results of vaccination
82. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP)
83. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia
84. Attenuated varicella virus vaccine in children with renal transplants
85. Measles vaccine
86. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis
87. Response to measles-mumps-rubella vaccine in children on dialysis
88. Measles vaccination after orthotopic liver transplantation
89. Spectrum of Haemophilus influenzae type b disease in adults
90. Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance
91. The 1996 Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide vaccines
92. Immune response to Haemophilus influenzae type b vaccination in renal transplant recipients with well-functioning allografts
93. Haemophilus influenzae immunisation and timing of cardiac transplantation